Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

Core Insights - Alector, Inc. has completed enrollment ahead of schedule in the PROGRESS-AD Phase 2 clinical trial, which evaluates the safety and efficacy of AL101/GSK4527226 in slowing the progression of early Alzheimer's disease [2][4] - The trial is a randomized, double-blind, placebo-controlled study that aims to assess disease progression using the Clinical Dementia Rating Sum of Boxes (CDR-SB) as the primary endpoint [4] Company Overview - Alector is a late-stage clinical biotechnology company focused on developing therapies for neurodegenerative diseases, leveraging genetics, immunology, and neuroscience [8][9] - The company is advancing a portfolio of programs targeting conditions such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease [8] Product Development - AL101/GSK4527226 is an investigational human monoclonal antibody designed to elevate progranulin levels in the brain, which is linked to neurodegenerative disorders [3][6] - The collaboration with GSK includes a $700 million upfront payment and potential additional milestone payments of up to $1.5 billion [7] Clinical Trial Details - The PROGRESS-AD trial is being conducted at multiple sites globally, evaluating two dose levels of AL101 [4] - The trial also includes various clinical and functional outcome assessments beyond the primary endpoint [4]